Methadone: A new old drug with promises and pitfalls

Current Pain and Headache Reports

Volumn 13, Issue 1, 2009, Pages 24-30

  Trafton, Jodie A ^a   Ramani, Abhinav ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DEXTROMETHADONE; LEVOMETHADONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OPIATE; OXYCODONE; SEDATIVE AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; DESENSITIZATION; DRUG ABSORPTION; DRUG ABUSE; DRUG ACTIVATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; NOCICEPTION; NONHUMAN; PAIN; PAIN ASSESSMENT; PATIENT CARE; QT INTERVAL; QT PROLONGATION; REVIEW; SENSITIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; HUMANS; METHADONE; OPIOID-RELATED DISORDERS;

EID: 59149103082     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0006-0     Document Type: Review

References (44)

1. BrownAR, Kraus C, Fleming M, et al.: Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J 2004, 80:654-659.
2. Leavitt SB, Shinderman M, Maxwell S, et al.: When "enough" is not enough: New perspectives on optimal methadone maintenance dose. Mt Sinai J Med 2000, 67:404-411.
3. Crettol S, Deglon JJ, Besson J, et al.: ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006, 80:668-681.
4. GarriAo MJ, Troconiz IF: Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999, 42:61-66.
5. Duché JC, Urien S, Simon N, et al.: Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000, 33:197-202.
6. Kristensen K, Christensen CB, Christrup LL: The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995, 56:45-50.
7. Scott CC, Robbins EB, Chen KK: Pharmacological comparison of the optical isomers of methadone. J Pharmacol Exp Ther 1948, 93:282-286.
8. Ingoglia NA, Dole VP: Localization of d- and l-methadone after intraventricular injection into rat brains. J Pharmacol Exp Ther 1970, 175:84-87.
9. Gorman AL, Elliott KJ, Inturrisi CE: The d- and l-isomers of methadone bind to the non-competitive site on the Nmethyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997, 223:1-4.
10. Davis WR, Johnson BD: Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend 2008, 92:267-276.
11. Dunbar S, Yaksh TL: Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Anesthesiology 1996, 84:1177-1188.
12. Jhamandas KH, Marsala M, Ibuki T, et al.: Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J Neurosci 1996, 16:2758-2766.
13. Inturrisi CE: The role of N-methyl-D-aspartate (NMDA) receptors in pain and morphine tolerance. Minerva Anestesiol 2005, 71:401-403.
14. Mendez IA, Trujillo KA: NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology 2008, 196:497-509.
15. Ibuki T, Marsala M, Masuyama T, et al.: Spinal amino acid release and repeated withdrawal in spinal morphine tolerant rats. Br J Pharmacol 2003, 138:689-697.
16. Davis AM, Inturrisi CE: D-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999, 289:1048-1053.
17. Shimoyama N, Shimoyama M, Elliott KJ, et al.: D-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther 1997, 283:648-652.
18. Galer BS, Lee D, Ma T, et al.: MorphiDex (morphine sulfate/ dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 2005, 115:284-295.
19. Arttamangkul S, Quillinan N, Low M, et al.: Differential activation and trafficking of mu-opioid receptors in brain slices. Mol Pharmacol 2008, 74:972-979.
20. Martini L, Whistler JL: The role of mu-opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 2007, 17:556-564.
21. Kim JA, Bartlett S, He L, et al.: Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence. Curr Biol 2008, 18:129-135.
22. Eckholm E, Pierce O: Methadone rises as a painkiller with big risks. New York Times. August 16, 2008:A1.
23. Paulozzi LJ, Xi Y: Recent changes in drug poisoning mortality in the United States by urban rural status and by drug type. Pharmacoepidemiol Drug Saf 2008, 17:997-1005.
24. Paulozzi LJ, Ryan GW: Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006, 31:506-511.
25. Gilson AM, Ryan KM, Joranson DE, et al.: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004, 28:176-188.
26. Joranson DE, Ryan KM, Gilson AM, et al.: Trends in medical use and abuse of opioid analgesics. JAMA 2000, 283:1710-1714.
27. Wedman EF, Bigelow GE, Johnson RE, et al.: QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007, 167:2469-2475.
28. Woosley RL, Pearson EC: QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005, 14:747-753.
29. Al-Khatib SM, LaPointe NM, Allen C, et al.: What clinicians should know about the QT interval. JAMA 2003, 286:2120-2127.
30. Fredheim OMS, Moksnes K, Borchgrevink PC, et al.: Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008, 52:879-889.
31. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007, 4:CD005454.
32. McCance-Katz EF, Rainey PM, Friedland G, et al.: Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001, 10:296-307.
33. Chan GM, Stajic M, Marker EK, et al.: Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: Analysis of medical examiner data. Acad Emerg Med 2006, 13:543-547.
34. Grass H, Behnsen S, Kimont HG, et al.: Methadone and its role in drug-related fatalities in Cologne 1989-2000. Forensic Sci Int 2000, 132:195-200.
35. Cone EJ, Fant RV, Rohay JM, et al.: Oxycodone involvement in drug abuse deaths: A DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 2000, 27:57-67.
36. Sheedy DL, Garrick TM, Fortis AH, et al.: Changing trends in heroin-related deaths in Sydney, Australia: 1995 to 1999. Am J Addict 2003, 12:52-59.
37. Oliver P, Keen J: Concomitant drugs of misuse and drug using behaviours associated with fatal opiate-related poisonings in Sheffield, UK, 1997-2000. Addiction 2003, 98:191-197.
38. Mikolaenko I, Robinson CA Jr, Davis GG: A review of methadone deaths in Jefferson County, Alabama. Am J Forensic Med Pathol 2002, 23:299-304.
39. Shields LB, Hunsaker III JC, Corey TS, et al.: Methadone toxicity fatalities: A review of medical examiner cases in a large metropolitan area. J Forensic Sci 2007, 52:1389-1395.
40. Iguchi MY, Handelsman L, Bickel WK, Griffiths RR: Benzodiazepine and sedative use/abuse by methadone clients. Drug Alcohol Depend 1993, 32:257-266.
41. Bespalov AY, Zvartau EE, Beardsley PM: Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. Neurosci Biobehav Rev 2001, 25:343-353.
42. Mitchell JM, Basbaum AI, Fields HL: A locus and mechanism of action for associative morphine tolerance. Nat Neurosci 2000, 3:47-53.
43. Andersen G, Christrup L, Sjøgren P: Relationships among morphine metabolism, pain and side effects during long-term treatment: An update. J Pain Symptom Manage 2003, 25:74-91.
44. Weschules DJ, Bain KT: A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 2008, 9:595-612.